PPD study researching one-dose solution
PPD can leave you feeling lost, but there is hope for relief. Join us in a research study to learn whether a novel investigational treatment can improve symptoms of PPD in women like you — with a single dose. If you qualify, you’ll receive support every step of the way, including compensation for your time.
Check your eligibility
Fill out the questions below to see if you meet the basic study requirements. Completing the questions below doesn’t mean that you will be enrolled in the study. There may be more eligibility criteria for the study.
Exploring a potentially new approach to treating PPD
This study is exploring an investigational treatment (RE104) for PPD to see if it is effective in providing relief with just a single dose. RE104 is a psychedelic, a class of drugs that have shown promise in reducing depressive symptoms in some people. Now, it’s time to learn if they help with PPD.
Why participate?
Specific benefits vary by location and may include:
Compensation
Get paid for your time and participation in the study
Travel reimbursement
Claim your travel-related costs and expenses
Feeding support
Access infant formula for your baby (where available)
Attentive care
Count on the medical team to support you throughout the study
Frequently Asked Questions
What is the investigational treatment?
The investigational treatment, RE104, is being developed as a potential new treatment for postpartum depression (PPD). It’s a psychedelic, similar to psilocybin (also known as magic mushrooms). It’s being studied to see if it can reduce depressive symptoms for people with PPD.
Will everyone receive the investigational treatment?
Yes. If you decide to participate, you will be randomly assigned (like a coin toss) to receive a low or a high dose of the investigational treatment.
How does the study work?
The study will compare the effects of 2 different doses of a study drug, RE104 — a low dose and a high dose. At the study clinic, you will receive a one-time injection of the investigational treatment. The study team will be on-site to closely monitor you during the entire treatment, which can last up to 10 hours. They will continue to track your health and PPD symptoms for another 4 weeks, both in-person and virtually, to see how you are doing. The entire study may last up to 53 days.
Who is eligible to participate?
Women who have given birth within the past 12 months may be eligible to participate if they are between the ages of 18–45, are not breastfeeding (or are willing to stop entirely), and began experiencing symptoms of PPD in the second or third trimester of pregnancy or within four weeks after giving birth. Symptoms may include, but are not limited to, feelings of sadness, hopelessness or guilt; excessive worrying; or loss of interest in activities you once enjoyed.
Will I get paid to participate?
Yes. To support your commitment to the study, you will receive monetary compensation for your time and reimbursement for your travel expenses. All study-related care costs will be covered in full. Additionally, you may be eligible to receive other assistance during treatment, such as financial aid towards buying infant formula.
Can I get pregnant or breastfeed as a study participant?
No. You may not take part in this study if you are breastfeeding, pregnant, think that you may be pregnant, or are trying to get pregnant. You must have stopped breastfeeding before taking part in the study (your baby must already be permanently weaned) and you must not resume breastfeeding, even after the study has ended. Support may be available for women who need help accessing formula while enrolled in the study.
Who is sponsoring the study?
The study is sponsored by Reunion Neuroscience. This study is being conducted with approval from an institutional review board (IRB), an independent committee established to help protect the rights of research participants.